Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?

Zhaohui Liao Arter,1,2 Misako Nagasaka1– 3 1Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USA; 3St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence: Misako Nagasaka, De...

Full description

Bibliographic Details

Published in:	Lung Cancer: Targets and Therapy
Main Authors:	Arter ZL, Nagasaka M
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-07-01
Subjects:	egfr nsclc post-osimertinib targeted therapy
Online Access:	https://www.dovepress.com/spotlight-on-patritumab-deruxtecan-her3-dxd-from-herthena-lung01-is-a--peer-reviewed-fulltext-article-LCTT